Steroids and drotrecogin alfa (activated) for severe sepsis.
نویسنده
چکیده
1 Peterson MW, Fretz P. Patient utilization of information resources in a lung cancer clinic. Chest 2003; 123:452–457 2 Croft DR, Peterson MW. An evaluation of the quality and contents of asthma education on the World Wide Web. Chest 2002; 121:1301–1307 3 Peterson MW. Continuing medical education on the Internet: state of the art. J Contin Educ Health Prof 2000; 19:242–249 4 McClung HJ, Murray RD, Heitlinger LA. The Internet as a source of current patient information. Pediatrics 1998; 101:E2 5 Impicciatore P, Pandolfini C, Casella N, et al. Reliability of health information for the public on the World Wide Web: systematic survey of advice on managing fever in children at home. BMJ 1997; 314:1875–1879 6 Eysenbach G, Diepgen TL. Labeling and filtering of medical information on the Internet. Methods Inf Med 1999; 38:80–88
منابع مشابه
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
INTRODUCTION In a study conducted by Annane, patients with septic shock and unresponsive to adrenocorticotropic hormone stimulation receiving low-dose steroid therapy had prolonged survival but not significantly improved 28-day mortality. The present study examines intravenous steroid use in PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) patients meeting t...
متن کاملDrotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
We read with interest the recent commentary by Friedrich and colleagues [1] that reported a meta-analysis of the two placebo-controlled clinical trials of Drotrecogin alfa (activated) (Drot Aa): the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation of Severe Sepsis) [2] and ADDRESS (Administration of Drotrecogin Alfa [Activated] in Early Stage Severe Sepsis) [3] trials. Severa...
متن کاملCost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
Drotrecogin alfa (activated) (Xigris; Eli Lilly and Company, Indianapolis, IN) significantly reduced mortality in severe sepsis in the PROWESS trial. We evaluate the cost-effectiveness of drotrecogin alfa (activated) as an adjunct to standard therapy from the German healthcare payer's perspective with respect to patients with 1) severe sepsis and 2) severe sepsis and multiple organ failure the ...
متن کاملEvaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
OBJECTIVES The aim of this study was to assess the cost-effectiveness of drotrecogin alfa (activated) compared with best supportive care in a UK cohort of adult intensive-care patients with severe sepsis. METHODS A systematic review of evidence on the clinical- and cost-effectiveness of drotrecogin alfa (activated) was undertaken, and a decision-analytic model was developed to estimate the co...
متن کاملRecombinant human activated protein C for severe sepsis.
BACKGROUND Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in patients with severe sepsis. In this phase 3 trial, we assessed whether treatment with drotrecogin al...
متن کاملDrotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
We are pleased that Williams and coworkers [1] confirmed our random effects analysis [2], which relied on publicly available data. This analysis pooled the results from patients with Acute Physiology and Chronic Health Evaluation (APACHE) II scores of 25 or greater from the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation of Severe Sepsis) [3] and ADDRESS (Administration of D...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Chest
دوره 124 5 شماره
صفحات -
تاریخ انتشار 2003